BC Week In Review | Jul 13, 2017
Clinical News

Neurotech's NT-501 meets in Phase II for macular telangiectasia

Neurotech Pharmaceuticals Inc. (Cumberland, R.I.) reported data from a Phase II trial in 67 patients with macular telangiectasia showing that implanted Renexus (NT-501) met the primary endpoint of reducing progressive loss of photoreceptors from baseline...
BC Innovations | Dec 3, 2015
Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
BC Week In Review | Sep 7, 2015
Clinical News

NT-503 ECT: Phase II started

Neurotech began a double-blind, U.S. and Israeli Phase II trial to compare a single NT-503 ECT implant vs. IV Eylea every 8 weeks in about 150 patients who have been treated with >=3 anti-VEGF injections...
BC Extra | Apr 16, 2015
Company News

Management tracks

Merck KGaA (Xetra:MRK) said Udit Batra will become head of its combined life sciences business, pending completion in mid-2015 of its planned acquisition of Sigma-Aldrich Corp. (NASDAQ:SIAL). Batra has been CEO and president of Merck...
BC Extra | Mar 20, 2015
Company News

Management tracks

Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc. , which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Ophthalmic play Neurotech Pharmaceuticals...
BioCentury | Oct 31, 2011
Finance

Evans rumors abound

Evans rumors abound Rumors have been bubbling up about Sir Christopher Evans, whose Excalibur Group has not disclosed an investment since 2008. Leaked details from early investor pitches suggest the Excalibur chairman is raising a...
BC Week In Review | Sep 6, 2010
Clinical News

AAD-2004: Phase I started

Neurotech began a double-blind, placebo-controlled Phase I trial to evaluate AAD-2004 in 32 healthy volunteers. Neurotech Pharmaceuticals Inc. , Lincoln, R.I.   Product: AAD-2004   Business: Neurology   Molecular target: Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1)...
BC Innovations | Jun 24, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ciliary neurotrophic factor (CNTF) A study in cell culture and in mice suggests that antagonizing CNTF could help treat AD. In...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BC Innovations | Sep 24, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinitis Rhodopsin (RHO; OPN2); ER-associated protein degradation (ERAD) Studies in Drosophila suggest that agonizing the ERAD pathway could help treat autosomal dominant retinitis pigmentosa....
Items per page:
1 - 10 of 20
BC Week In Review | Jul 13, 2017
Clinical News

Neurotech's NT-501 meets in Phase II for macular telangiectasia

Neurotech Pharmaceuticals Inc. (Cumberland, R.I.) reported data from a Phase II trial in 67 patients with macular telangiectasia showing that implanted Renexus (NT-501) met the primary endpoint of reducing progressive loss of photoreceptors from baseline...
BC Innovations | Dec 3, 2015
Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
BC Week In Review | Sep 7, 2015
Clinical News

NT-503 ECT: Phase II started

Neurotech began a double-blind, U.S. and Israeli Phase II trial to compare a single NT-503 ECT implant vs. IV Eylea every 8 weeks in about 150 patients who have been treated with >=3 anti-VEGF injections...
BC Extra | Apr 16, 2015
Company News

Management tracks

Merck KGaA (Xetra:MRK) said Udit Batra will become head of its combined life sciences business, pending completion in mid-2015 of its planned acquisition of Sigma-Aldrich Corp. (NASDAQ:SIAL). Batra has been CEO and president of Merck...
BC Extra | Mar 20, 2015
Company News

Management tracks

Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc. , which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA). Ophthalmic play Neurotech Pharmaceuticals...
BioCentury | Oct 31, 2011
Finance

Evans rumors abound

Evans rumors abound Rumors have been bubbling up about Sir Christopher Evans, whose Excalibur Group has not disclosed an investment since 2008. Leaked details from early investor pitches suggest the Excalibur chairman is raising a...
BC Week In Review | Sep 6, 2010
Clinical News

AAD-2004: Phase I started

Neurotech began a double-blind, placebo-controlled Phase I trial to evaluate AAD-2004 in 32 healthy volunteers. Neurotech Pharmaceuticals Inc. , Lincoln, R.I.   Product: AAD-2004   Business: Neurology   Molecular target: Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1)...
BC Innovations | Jun 24, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ciliary neurotrophic factor (CNTF) A study in cell culture and in mice suggests that antagonizing CNTF could help treat AD. In...
BioCentury | May 31, 2010
Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
BC Innovations | Sep 24, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinitis Rhodopsin (RHO; OPN2); ER-associated protein degradation (ERAD) Studies in Drosophila suggest that agonizing the ERAD pathway could help treat autosomal dominant retinitis pigmentosa....
Items per page:
1 - 10 of 20